000165252 001__ 165252
000165252 005__ 20251219174252.0
000165252 0247_ $$2doi$$a10.1007/s10792-025-03840-8
000165252 0248_ $$2sideral$$a146715
000165252 037__ $$aART-2026-146715
000165252 041__ $$aeng
000165252 100__ $$0(orcid)0000-0002-4476-6003$$aBartol-Puyal, Francisco de Asís$$uUniversidad de Zaragoza
000165252 245__ $$aChoroidal changes after antiVEGF in neovascular age-related macular degeneration with type 1 and 3 macular neovascularization
000165252 260__ $$c2026
000165252 5060_ $$aAccess copy available to the general public$$fUnrestricted
000165252 5203_ $$aPurpose: To analyze choroidal thickness (CT) in patients with neovascular age-related macular degeneration (nAMD) with type 1 macular neovascularization (MNV) and type 3 (or retinal angiomatous proliferation) after antiVEGF treatment for two years.
Methods: Retrospective study enrolling Caucasian naïve patients with nAMD (type 1 MNV), and patients with type 3 MNV with no other ophthalmological disorders, and without switching treatment. Nine manual CT measurements were performed on optical coherence tomography (OCT) Spectralis (Heidelberg Engineering). Demographic data, smoking, disease activity, and number of injections, among others were recorded. Three visits were analyzed: pretreatment baseline visit, first and last visits with no disease activity.
Results:53 eyes of 53 patients with type 1 MNV, and 41 eyes of 41patients with type 3 MNV were analyzed. Both groups received the same number of injections (p = 0.282). Type 3 MNV patients showed lower CT (between 143.29 and 174.17μm) than type 1 MNV patients (between 169.91 and 220.17μm) in the baseline visit, but differences disappeared in first and last visits. Choroidal thinning was only observed in type 1 MNV patients between baseline and first visit (p < 0.05). In the las visit, they had a CT between 87 and 96% of baseline measurement. No other influencing factor was detected.
Conclusions: Patients with nAMD (type 1 MNV) have higher CT than patients with type 3. However, patients with type 1 MNV experience significant choroidal thinning, and CT is similar in both groups after antiVEGF treatment. Smoking, type of drusen or other OCT features have no influence in this reduction
000165252 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000165252 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000165252 700__ $$aSánchez Monroy, Jorge$$uUniversidad de Zaragoza
000165252 700__ $$aPuzo Bayod, Martín
000165252 700__ $$aMallén, Víctor$$uUniversidad de Zaragoza
000165252 700__ $$0(orcid)0000-0001-6072-1545$$aMéndez-Martínez, Silvia$$uUniversidad de Zaragoza
000165252 700__ $$aCalvo, Pilar$$uUniversidad de Zaragoza
000165252 700__ $$0(orcid)0000-0003-2389-8282$$aPablo, Luis$$uUniversidad de Zaragoza
000165252 7102_ $$11013$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Oftalmología
000165252 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000165252 773__ $$g46, 1 (2026), [8 pp.]$$pInt. ophthalmol.$$tInternational Ophthalmology$$x0165-5701
000165252 8564_ $$s616189$$uhttps://zaguan.unizar.es/record/165252/files/texto_completo.pdf$$yVersión publicada
000165252 8564_ $$s1838079$$uhttps://zaguan.unizar.es/record/165252/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000165252 909CO $$ooai:zaguan.unizar.es:165252$$particulos$$pdriver
000165252 951__ $$a2025-12-19-14:43:50
000165252 980__ $$aARTICLE